GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » COGS-to-Revenue

Delcath Systems (STU:DV3R) COGS-to-Revenue : 0.15 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Delcath Systems COGS-to-Revenue?

Delcath Systems's Cost of Goods Sold for the three months ended in Sep. 2024 was €1.48 Mil. Its Revenue for the three months ended in Sep. 2024 was €10.09 Mil.

Delcath Systems's COGS to Revenue for the three months ended in Sep. 2024 was 0.15.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Delcath Systems's Gross Margin % for the three months ended in Sep. 2024 was 85.36%.


Delcath Systems COGS-to-Revenue Historical Data

The historical data trend for Delcath Systems's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems COGS-to-Revenue Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.39 0.19 0.25 0.31

Delcath Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.32 0.29 0.20 0.15

Delcath Systems COGS-to-Revenue Calculation

Delcath Systems's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.583 / 1.894
=0.31

Delcath Systems's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.477 / 10.091
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (STU:DV3R) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Delcath Systems's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.477 / 10.091
=85.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Delcath Systems COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Delcath Systems's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems Business Description

Traded in Other Exchanges
Address
566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems Headlines

No Headlines